

Belantamab mafodotin

Cat. No.:	HY-P3239
CAS No.:	2050232-20-5
Target:	Antibody-Drug Conjugates (ADCs)
Pathway:	Antibody-drug Conjugate/ADC Related
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Belantamab mafodotin (GSK2857916) is composed of humanized and focused monoclonal antibody against B cell maturation antigen (BCMA) and McMAAF. Belantamab mafodotin has anti-myeloma activity ^{[1][2]} .									
In Vitro	<p>Belantamab mafodotin binds to human BCMA protein with a K_d of 1 nM^[2].</p> <p>Belantamab mafodotin induces G2/M arrest in multiple myeloma cells in a dose and time dependent manner^[2].</p> <p>Belantamab mafodotin significantly promotes phagocytosis of multiple myeloma cells by human macrophages derived from macrophage colony-stimulating factor-stimulated monocytes^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>									
In Vivo	<p>Belantamab mafodotin significantly improves survival compared to vehicle in mice harbouring OPM2 tumours^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>Mice harbouring OPM2 tumours^[2]</td> </tr> <tr> <td>Dosage:</td> <td>4 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>IP, twice weekly for 4 doses</td> </tr> <tr> <td>Result:</td> <td>Significantly improves survival compared to vehicle.</td> </tr> </table>		Animal Model:	Mice harbouring OPM2 tumours ^[2]	Dosage:	4 mg/kg	Administration:	IP, twice weekly for 4 doses	Result:	Significantly improves survival compared to vehicle.
Animal Model:	Mice harbouring OPM2 tumours ^[2]									
Dosage:	4 mg/kg									
Administration:	IP, twice weekly for 4 doses									
Result:	Significantly improves survival compared to vehicle.									

REFERENCES

[1]. Hulin C, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. *Lancet Oncol.* 2020 Feb;21(2):207-221.

[2]. Markham A. Belantamab Mafodotin: First Approval. *Drugs.* 2020 Oct;80(15):1607-1613.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA